CO2021009261A2 - Complejo de gadolinio y un ligando quelatante derivado de pcta diastereoisoméricamente enriquecido y método de preparación y de purificación - Google Patents

Complejo de gadolinio y un ligando quelatante derivado de pcta diastereoisoméricamente enriquecido y método de preparación y de purificación

Info

Publication number
CO2021009261A2
CO2021009261A2 CONC2021/0009261A CO2021009261A CO2021009261A2 CO 2021009261 A2 CO2021009261 A2 CO 2021009261A2 CO 2021009261 A CO2021009261 A CO 2021009261A CO 2021009261 A2 CO2021009261 A2 CO 2021009261A2
Authority
CO
Colombia
Prior art keywords
complex
purification
preparation
pcta
gadolinium
Prior art date
Application number
CONC2021/0009261A
Other languages
English (en)
Spanish (es)
Inventor
Greneur Soizic Le
Alain Chénedé
Martine Cerf
Bruno François
Myriam Petta
Emmanuelle Marais
Caroline Robic
Stéphanie Louguet
Original Assignee
Guerbet Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guerbet Sa filed Critical Guerbet Sa
Publication of CO2021009261A2 publication Critical patent/CO2021009261A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CONC2021/0009261A 2019-01-17 2021-07-15 Complejo de gadolinio y un ligando quelatante derivado de pcta diastereoisoméricamente enriquecido y método de preparación y de purificación CO2021009261A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1900432A FR3091873B1 (fr) 2019-01-17 2019-01-17 Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de preparation et de purification
PCT/EP2020/051153 WO2020148436A1 (fr) 2019-01-17 2020-01-17 Complexe de gadolinium et d'un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de preparation et de purification

Publications (1)

Publication Number Publication Date
CO2021009261A2 true CO2021009261A2 (es) 2021-12-10

Family

ID=67001953

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0009261A CO2021009261A2 (es) 2019-01-17 2021-07-15 Complejo de gadolinio y un ligando quelatante derivado de pcta diastereoisoméricamente enriquecido y método de preparación y de purificación

Country Status (28)

Country Link
US (3) US11590246B2 (https=)
EP (2) EP3902800B1 (https=)
JP (2) JP7071596B2 (https=)
KR (2) KR102438394B1 (https=)
CN (3) CN113646308B (https=)
AR (1) AR117835A1 (https=)
AU (1) AU2020208794B2 (https=)
BR (1) BR112021014006B1 (https=)
CA (1) CA3126268C (https=)
CL (1) CL2021001868A1 (https=)
CO (1) CO2021009261A2 (https=)
DK (2) DK3943493T3 (https=)
ES (2) ES2930136T3 (https=)
FI (1) FI3943493T3 (https=)
FR (1) FR3091873B1 (https=)
HR (2) HRP20230678T1 (https=)
HU (2) HUE062554T2 (https=)
IL (1) IL284884B2 (https=)
MA (2) MA54626A (https=)
MX (1) MX2021008651A (https=)
PH (1) PH12021551725A1 (https=)
PL (2) PL3943493T3 (https=)
PT (2) PT3943493T (https=)
RS (1) RS64334B1 (https=)
SG (1) SG11202107779SA (https=)
TW (1) TWI811518B (https=)
WO (1) WO2020148436A1 (https=)
ZA (1) ZA202104994B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT4151637T (pt) 2018-08-06 2025-03-26 Bracco Imaging Spa Agentes de contraste à base de pcta que suportam gadolínio
FR3091873B1 (fr) * 2019-01-17 2020-12-25 Guerbet Sa Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de preparation et de purification
FR3091872B1 (fr) * 2019-01-17 2020-12-25 Guerbet Sa Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de synthese
KR20230041007A (ko) * 2020-07-17 2023-03-23 게르브 Pcta로부터 유도된 킬레이팅 리간드의 제조 방법
KR20230074593A (ko) * 2020-10-02 2023-05-30 이글 하버 테크놀로지스, 인코포레이티드 이온 전류 드룹 보상
WO2024049087A1 (ko) * 2022-09-01 2024-03-07 주식회사 테라노큐어 신규한 화합물 및 이를 포함하는 mri 조영제
KR102845061B1 (ko) * 2022-09-01 2025-08-13 주식회사 테라노큐어 신규한 화합물 및 이를 포함하는 mri 조영제
WO2026027591A1 (en) 2024-07-31 2026-02-05 Bracco Imaging Spa Synthesis of an intermediate of a gadolinium-based contrast agent

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
DE3640708C2 (de) 1986-11-28 1995-05-18 Schering Ag Verbesserte metallhaltige Pharmazeutika
DE4001655A1 (de) 1990-01-18 1991-07-25 Schering Ag 6-ring enthaltende makrocyclische tetraaza-verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
JPH04154729A (ja) 1990-10-16 1992-05-27 Nippon Mejifuijitsukusu Kk 磁気共鳴造影剤
IT1292128B1 (it) 1997-06-11 1999-01-25 Bracco Spa Processo per la preparazione di chelanti macrociclici e loro chelati con ioni metallici paramagnetici
EP0992245A1 (en) 1998-09-16 2000-04-12 Goldham Bioglan Pharma GmbH Radio-contrast agents
FR2793795B1 (fr) * 1999-05-21 2001-08-03 Guerbet Sa Isomeres de tetramides du complexe de gadolinium de l'acide (1,4,7,10-tetrazacyclododecane)1,4,7,10-tetra(2-glutarique) leur procede de preparation et leur application en imagerie medicale
FR2794744B1 (fr) 1999-06-09 2001-09-21 Guerbet Sa Complexes metalliques de polyaminoacides bicycliques, leur procede de preparation et leur application en imagerie medicale
FR2891830B1 (fr) 2005-10-07 2011-06-24 Guerbet Sa Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
US20090208421A1 (en) * 2008-02-19 2009-08-20 Dominique Meyer Process for preparing a pharmaceutical formulation of contrast agents
US8119817B2 (en) * 2009-09-29 2012-02-21 Degussa-Huels Ag Process for separating the diastereomers of RSS-and SSS-N- α [1-carboxy-3-phenylpropyl] lysylproline
EP2786768A1 (en) 2013-04-04 2014-10-08 Agfa Healthcare Process for preparing a material comprising a macrocyclic ligand and for producing a pharmaceutical formulation comprising said ligand with a lanthanide
CN105142649A (zh) * 2013-04-26 2015-12-09 法国加柏公司 造影剂配制品与有关制备方法
CN104188957B (zh) * 2014-05-28 2017-04-26 中国中医科学院西苑医院 一种防治再狭窄的药物及其制备和使用方法
WO2018199040A1 (ja) * 2017-04-28 2018-11-01 株式会社大塚製薬工場 クエン酸誘導体のジアステレオマーの製造方法
PT4151637T (pt) * 2018-08-06 2025-03-26 Bracco Imaging Spa Agentes de contraste à base de pcta que suportam gadolínio
FR3091873B1 (fr) * 2019-01-17 2020-12-25 Guerbet Sa Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de preparation et de purification
FR3091872B1 (fr) * 2019-01-17 2020-12-25 Guerbet Sa Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de synthese

Also Published As

Publication number Publication date
AU2020208794A1 (en) 2021-08-05
US20230149568A1 (en) 2023-05-18
KR102502862B1 (ko) 2023-02-23
WO2020148436A1 (fr) 2020-07-23
TWI811518B (zh) 2023-08-11
PT3943493T (pt) 2023-07-12
HUE060343T2 (hu) 2023-02-28
HRP20230678T1 (hr) 2023-09-29
CN113735854B (zh) 2024-05-14
FI3943493T3 (fi) 2023-07-19
CN113646308B (zh) 2024-12-13
MA55389A (fr) 2022-01-26
FR3091873B1 (fr) 2020-12-25
IL284884B2 (en) 2025-09-01
US12064487B2 (en) 2024-08-20
BR112021014006A2 (pt) 2021-09-21
CN113735854A (zh) 2021-12-03
EP3902800A1 (fr) 2021-11-03
CL2021001868A1 (es) 2022-01-21
HRP20221402T1 (hr) 2023-01-06
JP2022508496A (ja) 2022-01-19
KR102438394B1 (ko) 2022-09-01
ES2930136T3 (es) 2022-12-07
AR117835A1 (es) 2021-08-25
CA3126268A1 (fr) 2020-07-23
KR20210138134A (ko) 2021-11-18
PH12021551725A1 (en) 2022-04-11
US20240358863A1 (en) 2024-10-31
DK3943493T3 (da) 2023-07-24
ES2950118T3 (es) 2023-10-05
JP2022009463A (ja) 2022-01-14
TW202043227A (zh) 2020-12-01
PL3902800T3 (pl) 2022-12-27
EP3943493A1 (fr) 2022-01-26
JP7071596B2 (ja) 2022-05-19
JP7321230B2 (ja) 2023-08-04
MA54626A (fr) 2022-04-20
SG11202107779SA (en) 2021-08-30
PL3943493T3 (pl) 2023-08-07
RS64334B1 (sr) 2023-08-31
CN119552163A (zh) 2025-03-04
MX2021008651A (es) 2021-10-26
PT3902800T (pt) 2022-11-16
US20220062443A1 (en) 2022-03-03
FR3091873A1 (fr) 2020-07-24
AU2020208794B2 (en) 2023-01-12
EP3943493B1 (fr) 2023-04-19
IL284884A (en) 2021-08-31
DK3902800T3 (da) 2022-11-28
KR20210109039A (ko) 2021-09-03
CN113646308A (zh) 2021-11-12
ZA202104994B (en) 2023-04-26
BR112021014006B1 (pt) 2023-05-02
EP3902800B1 (fr) 2022-09-07
IL284884B1 (en) 2025-05-01
HUE062554T2 (hu) 2023-11-28
CA3126268C (fr) 2024-01-09
US11590246B2 (en) 2023-02-28

Similar Documents

Publication Publication Date Title
CO2021009261A2 (es) Complejo de gadolinio y un ligando quelatante derivado de pcta diastereoisoméricamente enriquecido y método de preparación y de purificación
CL2021001869A1 (es) Complejo de gadolinio y un ligando quelatante derivado de pcta diastereoisoméricamente enriquecido y método de síntesis.
CL2024000373A1 (es) Compuesto inductor de la degradación de plk1 novedoso
MX2025003876A (es) Compuestos para el tratamiento de enfermedades mediadas por alfa-1 antitripsina
UY39574A (es) Compuesto macrocíclico útil para tratar el cáncer y composición farmacéutica que lo contiene
BR112021006229A2 (pt) composto, composição farmacêutica, e, método para tratamento de um câncer
MX2023007554A (es) Compuesto espirocíclico como inhibidor del homólogo del oncogén viral del sarcoma 2 de rata de kirsten con mutación g12c (kras-g12c).
UY32096A (es) Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones
CL2018001210A1 (es) Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico.
AT507172A3 (de) Verfahren zur herstellung von dibenz (c,e) (1,2)- oxaphosphorin-derivaten, amino-dibenz (c,e) (1,2)-oxaphosphorin sowie deren verwendung
AR073845A1 (es) Derivados de acido l-glutamico y l-glutamina marcados con [f-18] (i), su uso y procedimiento para su preparacion y composiciones farmaceuticas
UY38941A (es) Nuevas sulfiliminas o sulfoximinas que contienen compuestos heterocíclicos fungicidas
MX2024005727A (es) Formulaciones estables que comprenden un anticuerpo biespecifico para bcma/cd3.
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
CO2022014837A2 (es) Células t v delta1+ para el tratamiento de neoplasias mieloides
CL2023003921A1 (es) Inhibidores de transglutaminasas
MX2017001459A (es) Sintesis de fosforamidatos.
UY29343A1 (es) Pirazolopiridinas y sales de las mismas, una composición farmacéutica que comprende dichos compuestos, un método para prepararlos y su uso.
CL2023003979A1 (es) Inhibidores de las transglutaminasas
UY38943A (es) Nuevas heteroaril piperidiniletanonas sustituidas de 6 miembros
MX2021012544A (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de enfermedades renales.
MX2016010952A (es) Nuevos derivados de cannabigerol.
ZA202006181B (en) Process for the preparation of iloprost
BR112018000811A2 (pt) composição de éster de fosfito
CO2024000832A2 (es) Inhibidores de transglutaminasas